Sulodexide is under clinical development by Alfasigma and currently in Phase III for Venous Thromboembolism. According to GlobalData, Phase III drugs for Venous Thromboembolism have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sulodexide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sulodexide overview
Sulodexide (Vessel, Vessel Due F, Aterina) is an anti-thrombolytic agent. It is formulated as soft gelatin capsules for oral route and solution for intravenous or intramuscular route of administration. Sulodexide is indicated for vascular disease with risk of thrombosis, it is also indicated for the treatment of chronic venous ulcers and chronic venous insufficiency.
The drug candidate is under development for the treatment of recurrent venous thromboembolism. The drug candidate was under development for the treatment of diabetic nephropathy, microalbuminuria, type 2 diabetes and chronic kidney disease, peripheral arterial obstructive disease and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Alfasigma overview
Alfasigma is a manufacturer and supplier of pharmaceutical products. The company offers prescription and over-the-counter drugs for the treatment of gastrointestinal disorders, drugs for diabetes and vascular diseases, nutraceuticals and medical foods. It also produces medicines to treat cardiology, orthopedics, rheumatology and broncho-pneumology indications. Alfasigma is investigating drugs against gastroenterology, vascular disease and neuroscience disorders. The company operates a contract manufacturing office in Alanno, Pescara, Italy. It has an operational presence in Belgium, Czech Republic, France, India, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovak Republic, Spain, Switzerland, Tunisia and the US. Alfasigma is headquartered in Bologna, Emilia-Romagna, Italy.
For a complete picture of Sulodexide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
